Evidence map›Paper›PMID 42344786›Full record

ArticleOpen forum infectious diseases2026

Severe Hospitalization-Requiring Viral Infection With Influenza or COVID-19: Metabolic Pathway Analysis.

Kirstine K Rasmussen, Wendy Bannister, Theis Itenov, Melissa Skeans, Sarah L Pett, Christine Wendt, Ken M Kunisaki, Gail Matthews, Alexander Jordan, Charlotte Suppli Ulrik and 8 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Kirstine K RasmussenCentre of Excellence for Health, Immunity and Infections, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-6071-7255
Wendy BannisterCentre of Excellence for Health, Immunity and Infections, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-4780-3364
Theis ItenovDepartment of Anesthesiology and Intensive Care, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Melissa SkeansDivision of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
Sarah L PettMRC Clinical Trials Unit, University College London, London, UK.
Christine WendtDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-0924-8745
Ken M KunisakiDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-8644-2827
Gail MatthewsTherapeutic Vaccine and Research Program, Kirby Institute, University of New South Wales, Sydney, Australia.
Alexander JordanCopenhagen Respiratory Research, Department of Medicine, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-5684-9375
Charlotte Suppli UlrikDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-8689-3695
Therese LapperreDepartment of Pulmonary Diseases, Bispebjerg Hospital, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-5176-0101
Rasmus Dahlin BojesenDepartment of Surgery, Zealand University Hospital, Køge, Denmark.ORCID https://orcid.org/0000-0003-3998-1160
Uffe BodtgerRespiratory Research Unit, Zealand University Hospital, Roskilde and Næstved, Denmark.ORCID https://orcid.org/0000-0002-1231-9209
Emma E IlettCentre of Excellence for Health, Immunity and Infections, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-4450-0010
Thomas BenfieldDepartment of Respiratory Medicine, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark.ORCID https://orcid.org/0000-0003-0698-9385
Pradeesh SivapalanDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-8620-3655
Daniel D MurrayCentre of Excellence for Health, Immunity and Infections, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Jens-Ulrik Stæhr JensenDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-4036-0521

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Influenza and SARS-CoV-2 can cause severe respiratory failure, but the metabolic pathways that lead to clinical deterioration are not fully uncovered. Tryptophan catabolism has been linked to disease progression and adverse outcomes. We aimed to find out whether the link between tryptophan catabolism and disease progression is shared by the 2 viral infections and, in an exploratory manner, to assess other metabolic pathways. Methods: Adults hospitalized due to influenza or SARS-CoV-2 from 3 prospective studies were pooled in a nested case-control study design. Cases were defined by disease progression: an increase in oxygen supplementation, intensive care unit admission, or death within 28 days. Cases were matched 1:2 to nonprogressors by pathogen and initial disease severity. We tested associations of plasma kynurenine, tryptophan, and the kynurenine/tryptophan ratio with disease progression. Metabolic profiles were investigated by unsupervised clustering-based, pathway-resolved methods. Results: We included 303 patients hospitalized with influenza or SARS-CoV-2. Higher levels of kynurenine and higher kynurenine/tryptophan ratios were associated with disease progression (odds ratio per log Conclusions: Several groups of metabolites were associated with disease progression independent of the pathogen. This indicates that biological mechanisms related to disease severity are shared in influenza and COVID-19. These mechanisms could be used for risk stratification of patients for potential disease-modifying treatments.

Indexed as

influenzakynureninemetabolomicsSARS-CoV-2tryptophan

Identifiers

PMID42344786
PMCPMC13288296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.